The Vasoactive Intestinal Polypeptide Receptor 2 pipeline drugs market research report outlays comprehensive information on the Vasoactive Intestinal Polypeptide Receptor 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Vasoactive Intestinal Polypeptide Receptor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Respiratory, Immunology, and Infectious Disease which include the indications Parkinson’s Disease, Schizophrenia, Acute Respiratory Distress Syndrome, Cystic Fibrosis, Sarcoidosis, Pulmonary Sarcoidosis, Coronavirus Disease 2019 (COVID-19), and Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome. It also reviews key players involved in Vasoactive Intestinal Polypeptide Receptor 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Vasoactive Intestinal Polypeptide Receptor 2 pipeline targets constitutes close to five molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase I, and Discovery stages are 1, 2, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Vasoactive Intestinal Polypeptide Receptor 2 overview
Vasoactive Intestinal Polypeptide Receptor 2 is a receptor that in humans is encoded by a gene VIPR2. Vasoactive intestinal polypeptide (VIP) is the ligand for this this receptor, which is a neuropeptide involved in various physiological processes. VIPR2 is a G protein-coupled receptor (GPCR) that transmits signals in response to binding with VIP. VIP is a peptide hormone that acts as a neurotransmitter and vasodilator. It is involved in the regulation of smooth muscle relaxation, secretion of various hormones, and immune system modulation. VIP binds to VIPR2 to initiate cellular responses. VIPR2 is expressed in various tissues, including the central nervous system, gastrointestinal tract, and immune cells. Modulating VIPR2 activity could have implications in conditions such as inflammatory disorders, gastrointestinal diseases, and circadian rhythm disorders.
For a complete picture of Vasoactive Intestinal Polypeptide Receptor 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
